Subcutaneous insulin resistance successfully circumvented on long term by peritoneal insulin delivery from an implantable pump in four diabetic patients

Diabetes and Metabolism

Volumn 31, Issue 5, 2005, Pages 496-498

  Riveline, J P ^a   Vantyghem, M C ^b   Fermon, C ^b   Brunet, C ^c   Gautier, J F ^d   Renard, E ^c   Charpentier, G ^a  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^b Service d'Endocrinologie et Métabolisme   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Diabetes; Implantable pump; Intraperitoneal insulin therapy; Subcutaneous insuline resistance

Indexed keywords

APROTININ; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RESISTANCE; INSULIN SENSITIVITY; KETOACIDOSIS; MALE; MINIPUMP; SKIN BIOPSY; TREATMENT OUTCOME;

EID: 27844578675     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70221-5     Document Type: Article

References (15)

1. Paulsen EP, Courtney JW, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 1979;28:640-5
2. Williams G, Pickup J, Clark A, Bowcock S, Cooke E, Keen H. Changes in blood flow close to subcutaneous insulin injection sites in stable and brittle diabetics. Diabetes 1983;32:466-73
3. Steel JM. "Such a nice girl". Lancet 1994;344:765-6
4. Vigouroux C, Magre J, Vantyghem MC, et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 2000;49:1958-62
5. Soudan B, Girardot C, Fermon C, Verlet E, Pattou F, Vantyghem MC. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab 2003;29:539-46
6. Tattersall RB. Brittle diabetes. Clin Endocrinol Metab 1977;6:406-19
7. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med 1986;315:147-53
8. Maberly GF, Wait GA, Kilpatrick JA, et al. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologia 1982;23:333-6
9. Freidenberg GR, White N, Cataland S, O'Dorisio TM, Sotos JF, Santiago JV. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N Engl J Med 1981;305:363-8
10. Muller WA, Taillens C, Lereret S, et al. Resistance against subcutaneous insulin successfully managed by aprotinin. Lancet 1980;7:1245-6
11. Brossard JH, Havrankova J, Rioux D, Bertrand S, D'Amour P. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance. Diabet Med 1993;10:174-6
12. Pickup JC, Home PD, Bilous RW, Keen H, Alberti KGMM. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. BMJ 1981;282:347-50
13. Schade DS, Eaton RP, Warhol RM, Gregory JA, Doberneck RC. Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin. Diabetes 1982;31:470-3
14. Campbell IW, Kritz H, Najemnik C, Hagmueller G, Irsigler K. Treatment of a type I diabetic with subcutaneous insulin resistance by a totally implantable insulin infusion device ("Infusaid"). Diabetes Res 1984;1:83-8
15. Dandona P, Fonseca V, Fernando O, et al. Control of diabetes through a subcutaneous peritoneal access device (SPAD) in patients with resistance to subcutaneously injected insulin. Diabetes Res 1987;5:47-9